Related references
Note: Only part of the references are listed.
Article
Infectious Diseases
Paul M. McKeigue et al.
Summary: The study investigated the association of primary acute cerebral venous thrombosis (CVT) with COVID-19 vaccination in the population of Scotland. The findings support a causal association between CVT and the AstraZeneca vaccine, but the absolute risk of post-vaccination CVT in Scotland was lower than in Scandinavia and Germany, and the reason for this difference is unclear.
BMC INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Lars Christian Lund et al.
Summary: This study examined prescription drug and healthcare utilization among individuals in Denmark who tested positive for SARS-CoV-2 but did not require hospital admission. The study found that these individuals had a low risk of severe post-acute complications, but showed increases in visits to general practitioners and outpatient hospital visits, indicating potential COVID-19 sequelae.
LANCET INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Nina H. Schultz et al.
Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Douglas B. Cines et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Andreas Greinacher et al.
Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Anton Pottegard et al.
Summary: This study assessed rates of cardiovascular and haemostatic events in Denmark and Norway after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S, finding increased rates of venous thromboembolic events among recipients. Despite slightly higher rates of thrombocytopenia/coagulation disorders and bleeding, the overall safety outcomes were largely reassuring.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
C. R. Simpson et al.
Summary: Analysis of data from the EAVE II cohort in Scotland has shown that a first dose of the ChAdOx1 nCoV-19 vaccine may be associated with increased risks of idiopathic thrombocytopenic purpura, arterial thromboembolic events, and hemorrhagic events. However, there were no positive associations found between the BNT162b2 vaccine and these adverse events.
Article
Medicine, General & Internal
Sue Pavord et al.
Summary: Phenotypes of VITT were defined in 220 patients in the United Kingdom who presented a median of 14 days after the first ChAdOx1 nCoV-19 vaccination. Half had cerebral venous sinus thrombosis, a third of whom also had intracranial hemorrhage. Mortality was 22%. Intravenous immune globulin may reverse VITT.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Pedro M. Folegatti et al.
Article
Health Care Sciences & Services
Heather J. Whitaker et al.
STATISTICAL METHODS IN MEDICAL RESEARCH
(2009)
